- TRADE NAME: Temodar (MSD)
- INDICATIONS: Anaplastic astrocytoma; newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment
- CLASS: Alkylating agent, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
- HALF-LIFE: 1.8 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Clozapine, Digoxin, Valproic Acid
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of temozolomide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 11/17/2024
